Results 71 to 80 of about 836,047 (311)

Perioperative carbohydrate loading in patients undergoing one-day surgery. A systematic review of randomized controlled trials

, 2022
INTRODUCTION: It is suggested that preoperative carbohydrate loading may have beneficial effects, which is emphasised in Enhanced Recovery After Surgery protocols (ERAS).
Jakub Kukliński, Steckiewicz, Karol P., Radosław Owczuk, Owczuk, Radosław, Kukliński, Jakub, Karol Steckiewicz   +5 more
core   +1 more source

Factors affecting patient participation in orthopaedic trials comparing surgery to non-surgical interventions

Contemporary Clinical Trials Communications, 2016
Background: Randomized controlled trials (RCTs) are considered the most robust research design to determine the effectiveness of interventions. RCTs comparing surgery to non-surgical alternatives are particularly difficult to perform, partly due to ...
Rajat Mittal, Ian A. Harris, Sam Adie, Justine M. Naylor   +3 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Randomized Controlled Trials Evaluating PCI.

, 2014
Randomized Controlled Trials Evaluating PCI.
Xiao-lian Song (605714), Shuan-shuan Xie (605712), Cai-cun Zhou (605713), Chang-hui Wang (605715), Ming Li (91180)   +4 more
core   +1 more source

Cluster‐randomized controlled trials: A tutorial

Cochrane Evidence Synthesis and Methods, 2023
This tutorial focuses on cluster-randomised controlled trials. We will explain what cluster-RCTs are, why they might be used, and how to include data from cluster-randomised controlled trials in systematic reviews. Accompanying the tutorial is a micro-learning module, which will give you the chance to practice adjusting data from cluster-randomised ...
Marty Chaplin, Kerry Dwan
openaire   +3 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Methodological progress note: Pilot randomized controlled trials

Definitive randomized controlled trials (RCTs) are the cornerstone of evidence-based medicine but can be complicated, protracted, and expensive. Given the challenges of large-scale trials, pilot trials serve as a crucial initial step, allowing for ...
Marsh, Nicole, Keogh, Samantha, Corley, Amanda   +2 more
core   +1 more source

Characteristics of randomized controlled trials.

, 2019
Characteristics of randomized controlled trials.
Javier Louro (8089580), Maria Sala (501415), Xavier Castells (34190), Laia Domingo (520014), Margarita Posso (3147807), Marta Román (501413)   +5 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source